New treatment for cough with capsaicin

Purpose and goal

The project follows the original goals with the exception of the study break during the ongoing Corona pandemic: To provide positive results in the ongoing clinical study, introduce a new cough medicine on the market. We collaborate with Synergon Patentbyrå AB and Hamilton Advokatbyrå KB for patent and IP issues. Approved patents are now available in Australia, Canada and Europe (EPO). The application is in the national phase for the USA. A number of contacts with the pharmaceutical industry have been completed and planned.

Expected results and effects

Available results of the clinical study, which is now on “pause”, have not been analyzed, but the study model worked excellently and is ready to be resumed. We had a very positive response from the patients. Because the study is randomized and double-blind, a significant weight would be lost in an early “pre-analysis”. We regard the three approved patents so far as a very positive result, as Europe in particular is well known for a complicated and difficult process in similar cases. The approved patents indicate large potential effects in the form of business opportunities.

Planned approach and implementation

We have developed a medicine based on capsaicin which is now being tested for the treatment of chronic cough in a phase 2 study. This clinical drug study follows a strict study protocol completely in accordance with the Swedish Medical Products Agency´s rules. The medicine has been developed by researchers at the University of Gothenburg, but patents and other rights have been transferred to a newly formed company. Three approved patents and one ongoing application for a user patent protect the product that has attracted the attention of the pharmaceutical industry.

External links

Presentation av FAMCAPSAB250 och projektet med capsaicinbehandling av kronisk hosta